Rapport Therapeutics's top three insider shareholders as of April 28, 2026 are Rock Ventures V, L.P. Third (TenPercentOwner, 8.10Mn shares), Rock Ventures V, L.P. Third (TenPercentOwner, 8.10Mn shares), Rock Ventures V, L.P. Third (TenPercentOwner, 8.10Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Rock Ventures V, L.P. Third | - | 7,135,233 | 969,218 | 10 Jun, 2024 |
| Rock Ventures V, L.P. Third | - | 7,135,233 | 969,218 | 10 Jun, 2024 |
| Rock Ventures V, L.P. Third | - | 7,135,233 | 969,218 | 10 Jun, 2024 |
| Rock Ventures V, L.P. Third | - | 6,709,228 | 0 | 21 Apr, 2026 |
| Venture Partners Xii, Llc Arch | - | 0 | 3,728,738 | 10 Jun, 2024 |
| Venture Partners Xii, Llc Arch | - | 0 | 3,728,738 | 10 Jun, 2024 |
| Venture Partners Xii, Llc Arch | - | 0 | 3,728,738 | 10 Jun, 2024 |
| Venture Partners Xii, Llc Arch | - | 0 | 3,728,738 | 10 Jun, 2024 |
| James Healy | - | 0 | 1,881,968 | 10 Jun, 2024 |
| Rock Ventures V, L.P. Third | - | 0 | 969,218 | 10 Jun, 2024 |
| Abraham Ceesay | Chief Executive Officer | 556,247 | 20,729 | 19 Feb, 2026 |
| David Bredt | Chief Scientific Officer | 393,075 | 0 | 19 Feb, 2026 |
| Krishnaswamy Yeleswaram | Chief Development Officer | 246,426 | 0 | 21 Apr, 2026 |
| Cheryl Gault | Chief Operating Officer | 159,914 | 0 | 31 Mar, 2026 |
| James Healy | - | 0 | 113,626 | 03 Jul, 2024 |
| Steven M Paul | - | 0 | 41,666 | 15 Sep, 2025 |
| Reid M Huber | - | 20,400 | 0 | 15 Sep, 2025 |
| Troy A. Ignelzi | Chief Financial Officer | 10,000 | 0 | 13 Mar, 2025 |
| Wendy B. Young | - | 9,500 | 0 | 11 Sep, 2025 |
| Wendy B. Young | - | 9,500 | 0 | 11 Sep, 2025 |
| Wendy B. Young | - | 9,500 | 0 | 11 Sep, 2025 |
| Wendy B. Young | - | 9,500 | 0 | 11 Sep, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 17 Apr, 2026 | Rock Ventures V, L.P. Third | Common Stock | D | 426,005 | $40.32 | 6,709,228 | D | S |
| 17 Apr, 2026 | Krishnaswamy Yeleswaram | Common Stock | D | 20,225 | $39.99 | 246,426 | D | S |
| 10 Apr, 2026 | Krishnaswamy Yeleswaram | Common Stock | D | 500 | $34.98 | 286,016 | D | S |
| 13 Apr, 2026 | Krishnaswamy Yeleswaram | Common Stock | D | 9,165 | $34.97 | 276,851 | D | S |
| 14 Apr, 2026 | Krishnaswamy Yeleswaram | Common Stock | D | 10,200 | $35.08 | 266,651 | D | S |
| 08 Apr, 2026 | Krishnaswamy Yeleswaram | Common Stock | D | 360 | $34.90 | 286,516 | D | S |
| 30 Mar, 2026 | Cheryl Gault | Common Stock | D | 7,161 | $28.04 | 162,753 | D | S |
| 30 Mar, 2026 | Cheryl Gault | Common Stock | D | 2,839 | $28.55 | 159,914 | D | S |
| 25 Mar, 2026 | Krishnaswamy Yeleswaram | Common Stock | D | 10,115 | $29.99 | 286,876 | D | S |
| 05 Mar, 2026 | Cheryl Gault | Common Stock | D | 2,014 | $28.93 | 169,914 | D | S |
| 17 Feb, 2026 | David Bredt | Common Stock | D | 900 | $28.02 | 394,675 | D | S |
| 18 Feb, 2026 | Abraham Ceesay | Common Stock | D | 3,552 | $29.05 | 558,528 | D | S |
| 17 Feb, 2026 | David Bredt | Common Stock | D | 5,400 | $28.95 | 389,275 | D | S |
| 18 Feb, 2026 | Abraham Ceesay | Common Stock | D | 2,281 | $29.80 | 556,247 | D | S |
| 17 Feb, 2026 | David Bredt | Common Stock | D | 2,200 | $29.59 | 387,075 | D | S |
| 18 Feb, 2026 | Abraham Ceesay | Common Stock | D | 2,983 | $29.04 | 22,829 | I | S |
| 18 Feb, 2026 | Abraham Ceesay | Common Stock | D | 2,100 | $29.80 | 20,729 | I | S |
| 19 Feb, 2026 | David Bredt | Common Stock | A | 6,000 | $1.80 | 393,075 | D | M |
| 19 Feb, 2026 | David Bredt | Stock Options (Right to Buy) | D | 6,000 | $0.00 | 88,080 | D | M |
| 02 Feb, 2026 | Jeffrey Sevigny | Stock Option (Right to Buy) | A | 130,000 | $0.00 | 130,000 | D | A |